Cargando…
Steady State Bioequivalence of Generic and Innovator Formulations of Stavudine, Lamivudine, and Nevirapine in HIV-Infected Ugandan Adults
BACKGROUND: Generic antiretroviral therapy is the mainstay of HIV treatment in resource-limited settings, yet there is little evidence confirming the bioequivalence of generic and brand name formulations. We compared the steady-state pharmacokinetics of lamivudine, stavudine and nevirapine in HIV-in...
Autores principales: | Byakika-Tusiime, Jayne, Chinn, Leslie W., Oyugi, Jessica H., Obua, Celestino, Bangsberg, David R., Kroetz, Deanna L. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2602850/ https://www.ncbi.nlm.nih.gov/pubmed/19096711 http://dx.doi.org/10.1371/journal.pone.0003981 |
Ejemplares similares
-
Free HIV Antiretroviral Therapy Enhances Adherence among Individuals on Stable Treatment: Implications for Potential Shortfalls in Free Antiretroviral Therapy
por: Byakika-Tusiime, Jayne, et al.
Publicado: (2013) -
The effects of highly active antiretroviral therapy (HAART) of stavudine, lamivudine and nevirapine on the CD4 lymphocyte count of HIV-infected Africans: the Nigerian experience
por: Erhabor, Osaro, et al.
Publicado: (2009) -
Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 ≥ 50 cells/mm(3)
por: Manosuthi, Weerawat, et al.
Publicado: (2007) -
Durability of Stavudine, Lamivudine and Nevirapine among Advanced HIV-1 Infected Patients with/without Prior Co-administration of Rifampicin: A 144-week Prospective Study
por: Manosuthi, Weerawat, et al.
Publicado: (2008) -
Renal impairment after switching from stavudine/lamivudine to tenofovir/lamivudine in NNRTI-based antiretroviral regimens
por: Manosuthi, Weerawat, et al.
Publicado: (2010)